STRATEC Biomedical (0RAR) Price & Analysis

1 Followers

0RAR Stock Chart & Stats

€22.20

-€0.45(-1.54%)

At close: Jan 09 4:00 PM EST

€22.20

-€0.45(-1.54%)

Day’s Range― - ―

52-Week Range€16.34 - €29.45

Previous CloseN/A

Volume10.00

Average Volume (3M)15.21K

Market Cap

€273.51M

Enterprise Value€300.91M

Total Cash (Recent Filing)€19.03M

Total Debt (Recent Filing)€115.72M

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Nov 12, 2026

EPS Estimate

0.15

Next Dividend Ex-DateN/A

Dividend Yield2.61%

Share Statistics

EPS (TTM)-0.04

Shares Outstanding12,157,841

10 Day Avg. Volume41,161

30 Day Avg. Volume15,209

Financial Highlights & Ratios

PEG Ratio11.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.09

P/FCF Ratio-28.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€29.00

Price Target Upside30.63% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)1.41

Revenue Forecast (FY)€267.01M

Bulls Say, Bears Say

Bulls Say

Systems Revenue GrowthStrong systems growth indicates continued demand for STRATEC’s core development and production platforms across several diagnostic applications. Expanding platform activity can support future instrument volumes, deepen customer relationships, and create recurring lifecycle opportunities as systems remain in use.

Cash Generation And Debt ReductionThe cash-flow turnaround and lower leverage improve financial flexibility and reduce balance-sheet risk. Positive free cash flow gives STRATEC greater capacity to fund product development, support customer programs, and manage working capital while strengthening resilience if demand remains uneven.

Regulatory-driven Lifecycle DemandRegulatory and cybersecurity requirements create a durable need for platform updates, documentation, software, and sustaining engineering. This supports STRATEC’s service offering beyond initial instrument sales and can reinforce recurring revenue as customers maintain compliant installed systems.

Bears Say

Revenue Contraction And Thin ProfitabilitySeveral years of revenue contraction have reduced operating leverage and left profitability near break-even. Thin EBIT and slightly negative net income weaken internal funding capacity and make sustained earnings improvement dependent on a credible recovery in volumes, mix, and execution.

Weak Consumables And Maintenance DemandWeak parts and consumables demand pressures a potentially recurring, higher-margin revenue stream tied to installed systems. If customer inventory reductions or integration actions persist, they could delay aftermarket normalization and limit margin recovery even when systems demand improves.

Inventory And Component PressuresElevated inventory ties up cash and raises the risk of slower turnover as legacy components and COVID-era products ramp below expectations. Electronic-component lead times and price volatility can also complicate production planning, availability, and margin protection over coming quarters.

STRATEC Biomedical News

Stratec Biomedical Earnings Call: Profit Rebound Amid Risks

STRATEC Biomedical (($DE:SBS)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

STRATEC Biomedical Balances Weak Q1 With Firm Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

5M ago

STRATEC Biomedical Balances Q1 Setback With Solid Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

5M ago

0RAR Upcoming Earnings Report: What to Expect?

STRATEC Biomedical (0RAR) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts...

7M ago

STRATEC Biomedical’s Earnings Call: Mixed Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q3 earnings call. Read on for the main highlights of the call....

11M ago

STRATEC Biomedical (0RAR) Unveils Dividend Details for Q3: Mark Your Calendar!

STRATEC Biomedical (LSE: 0RAR) has declared, under its dividend policy, a yearly cash dividend in the amount of...

1y ago

0RAR Earnings this Week: How Will it Perform?

STRATEC Biomedical (0RAR) is scheduled to report 3rd quarter earnings on 10/25/2024, before the market opens. Regarding Q3...

2y ago

German Market Update: Three Shares to Buy Today

The DAX 40 index traded 1.83% higher and closed at 15,232.8 points on Tuesday. This came as a...

4y ago

0RAR FAQ

What was STRATEC Biomedical AG’s price range in the past 12 months?

STRATEC Biomedical AG lowest share price was €16.34 and its highest was €29.45 in the past 12 months.

What is STRATEC Biomedical AG’s market cap?

STRATEC Biomedical AG’s market cap is €273.51M.

When is STRATEC Biomedical AG’s upcoming earnings report date?

STRATEC Biomedical AG’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.

How were STRATEC Biomedical AG’s earnings last quarter?

STRATEC Biomedical AG released its earnings results on Aug 14, 2026. The company reported €0.385 earnings per share for the quarter, beating the consensus estimate of €0.19 by €0.195.

Is STRATEC Biomedical AG overvalued?

According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does STRATEC Biomedical AG pay dividends?

STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.61%. See more information on STRATEC Biomedical AG dividends here

What is STRATEC Biomedical AG’s EPS estimate?

STRATEC Biomedical AG’s EPS estimate is 0.15.

How many shares outstanding does STRATEC Biomedical AG have?

STRATEC Biomedical AG has 12,157,841 shares outstanding.

What happened to STRATEC Biomedical AG’s price movement after its last earnings report?

STRATEC Biomedical AG reported an EPS of €0.385 in its last earnings report, beating expectations of €0.19. Following the earnings report the stock price went up 6.956%.

Which hedge fund is a major shareholder of STRATEC Biomedical AG?

Currently, no hedge funds are holding shares in GB:0RAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

STRATEC Biomedical Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€29.00 (30.63% Upside)

Technicals

Fundamentals

Return on Equity

-0.17%

Trailing 12-Months

Asset Growth

―

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

STRATEC Biomedical AG

Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.

STRATEC Biomedical (0RAR) Earnings & Revenues

Historic Earnings Reports

0RAR Stock 12 Month Forecast

Average Price Target

€29.00

▲(30.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","38":"€38","20.75":"€20.8","26.5":"€26.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,20.75,26.5,32.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.861,23.025538461538464,24.190076923076923,25.354615384615386,26.51915384615385,27.683692307692308,28.84823076923077,30.01276923076923,31.177307692307693,32.341846153846156,33.50638461538462,34.670923076923074,35.83546153846154,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.861,22.410153846153847,22.959307692307693,23.50846153846154,24.057615384615385,24.60676923076923,25.155923076923077,25.705076923076923,26.25423076923077,26.803384615384616,27.35253846153846,27.901692307692308,28.450846153846154,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.861,21.79476923076923,21.728538461538463,21.662307692307692,21.596076923076925,21.529846153846155,21.463615384615384,21.397384615384617,21.331153846153846,21.264923076923075,21.19869230769231,21.132461538461538,21.06623076923077,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.964,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.339,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.517,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.431,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.018,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.001,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.465,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.861,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >